Jim Cramer is reportedly optimistic about Johnson & Johnson (JNJ), with the pharma giant’s shares significantly up over the past year. RBC Capital and Bank of America have both raised their price targets for JNJ, citing strong finances and organic growth. The company’s 2025 revenue reached $94.2 billion, with a projected increase to $100.5 billion in 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer
Jim Cramer is reportedly optimistic about Johnson & Johnson (JNJ), with the pharma giant’s shares significantly up over the past year. RBC Capital and Bank of America have both raised their price targets for JNJ, citing strong finances and organic growth. The company’s 2025 revenue reached $94.2 billion, with a projected increase to $100.5 billion in 2026.